3 US Growth Stocks Riding AI Hardware And Advanced Healthcare Demand

Strong U.S. growth, rising incomes and a steady stream of new businesses are giving small and mid caps plenty of attention, even as tariffs, higher inflation and geopolitical risks keep investors on edge. That mix of support and stress can matter more for smaller companies, which tend to be closer to the domestic economy. This article looks at three US Small and Mid Cap Growth Stocks from our screener that appear especially exposed to these trends. You will see how each stock might benefit from, or be challenged by, the current macro backdrop so you can decide whether they deserve a closer look.

Amtech Systems (ASYS)

Overview: Amtech Systems makes equipment and consumables that chip makers and electronics manufacturers use to heat, clean, polish and package semiconductor wafers and advanced electronic components across the US, Asia and Europe.

Operations: Amtech Systems generates around US$57.5 million from Thermal Processing Solutions and US$21.3 million from Material and Substrate, with revenue concentrated in the United States at about US$45.4 million and China at about US$35.1 million.

Market Cap: US$258.6 million

Investors looking at Amtech Systems are seeing a small US manufacturer tied directly to the build out of AI hardware, with more than 30% of its Thermal Processing Solutions segment already linked to AI products and company wide bookings recently running ahead of sales. The business is also leaning more on higher margin recurring consumables and services, which can help smooth out the usual ups and downs of semiconductor equipment demand. At the same time, the stock carries a high P/E multiple and depends heavily on AI related capital spending and mature chip markets, so setbacks in those areas or in the tariff backdrop could have a negative impact. The real question is whether the current price fairly reflects that mix of momentum and risk.

Amtech Systems’ AI linked bookings and high P/E suggest the story might be bigger than a simple semiconductor cycle play. See how the 2 key rewards and 2 important warning signs could shift your view on what really drives this stock.

Vericel (VCEL)

Overview: Vericel develops and sells cell based therapies and biologic products that help repair knee cartilage for sports medicine patients and treat severe burns, with MACI for knee defects, Epicel for extensive skin loss and NexoBrid for burn eschar removal across North America.

Market Cap: US$2.44b

Vericel provides exposure to a focused portfolio of advanced therapies in sports medicine and burn care, supported by a growing surgeon base, high payer acceptance and an expanding addressable market that management is working to extend into new indications like MACI Ankle. The company has reported revenue and earnings growth in recent years, with improving margins and guidance that indicates management’s confidence in its product franchises. However, the stock trades at a very high P/E and relies on a narrow set of products and external borrowing. Combined with recent insider selling and execution risk around new facilities and label expansions, this creates a higher risk profile that may warrant closer scrutiny.

Vericel’s high P/E and focused therapy portfolio suggest the story may not be fully priced in yet, especially with label expansions on the table. Get the full context in the analyst forecasts for Vericel to see what might be hiding in plain sight.

ADMA Biologics (ADMA)

Overview: ADMA Biologics develops, manufactures and sells plasma derived biologic therapies that help treat immune deficiencies and certain infectious disease risks, with a portfolio that includes IVIG products BIVIGAM and ASCENIV and the Hepatitis B product Nabi HB, supported by its own plasma collection network.

Operations: ADMA Biologics generates about US$493.0 million from ADMA Biomanufacturing, US$16.7 million from Plasma Collection Centers and US$0.1 million from unallocated license revenues, with roughly US$506.8 million of sales coming from the United States and a small contribution from international markets.

Market Cap: US$2.0b

ADMA Biologics is drawing attention because it combines high profitability metrics, including a ROE above 40% and net margins above 30%, with strong revenue momentum in core products like ASCENIV and BIVIGAM that are tied to ongoing US healthcare demand. The stock screens as deeply undervalued on several measures, even as analysts and management point to rising free cash flow, share buybacks and expanded indications such as ASCENIV for younger pediatric patients. On the flip side, ADMA relies heavily on a narrow product set, carries funding risk from external borrowing and now faces a securities class action that could weigh on sentiment. The key question for investors is whether the current price fairly reflects this mix of quality, controversy and growth potential.

ADMA Biologics pairs high ROE and strong margins with a stock that screens as deeply undervalued. Get the analysis report for ADMA Biologics to see what might be masking the full story.

The three stocks in this list are just the starting point, since the full US Small- and Mid-Cap Growth Stocks screener surfaced 16 more US small and mid caps with equally compelling growth and financial health stories. Use Simply Wall St to identify and analyze the specific catalysts and narratives that matter to you, so you can focus on the highest conviction opportunities.

Take Control of Your Investment Journey

If Vericel or any of these companies sound like a great opportunity, register for FREE with Simply Wall St and add your companies to a Watchlist to monitor the share price against the fair value the ideal entry point. Once you've made your move, manage your holdings with our Portfolio Command Center that filters out the noise to deliver only the most critical, actionable updates. Throughout your journey, our Community allows you to filter the best ideas from thousands of investor perspectives. By uncovering hidden catalysts and risks early, you'll accelerate your decision-making and stay one step ahead of the market.

Seeking Fresh Alternatives Before They Fly

New stock ideas can move from quiet to breakout quickly. Use fresh screeners to spot momentum while it matters, before the crowd catches up. Get in early.

• Find resilient companies before they get crowded by scanning the 81 resilient stocks with low risk scores. Focus on those that show momentum and financial discipline while they remain under the radar.
• Look for structural trends in automation by targeting the 35 robotics and automation stocks, where cash flows, balance sheets and demand drivers may be aligned before valuations move higher.
• Consider potential infrastructure shifts by checking the 35 power grid technology and infrastructure stocks, which may be positioned to benefit if grid spending accelerates and capital flows increase into the sector.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com